All In Biotech

Drug Trial Radar · NCT07083960

OM336 in Autoimmune Cytopenias

An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias

Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Aug 1, 2025

Primary completion

Dec 2026

Study completion Sep 2027

Sponsor

Sponsor type
Industry
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.

Conditions

  • AIHA - Warm Autoimmune Hemolytic Anemia
  • AIHA - Cold Autoimmune Hemolytic Anemia
  • ITP - Immune Thrombocytopenia

Interventions

  • OM336Drug

    OM336 is an engineered bispecific antibody directed against BCMA and CD3

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and TolerabilityTime frame: 12 weeks

Locations

7 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • Medstar

    Washington D.C., District of Columbia · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • The Canberra Hospital

    Canberra, Australian Capital Territory, Australia · Recruiting

  • Liverpool Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Icon Cancer Center South Brisbane

    Brisbane, Queensland, Australia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.